BMB Reports Papers in Press available online.

Search Papers In Press
This galley proof is being listed electronically before publishing the final manuscript (It's not final version).

Elevated Plasma メ1-Antichymotrypsin is a Biomarker Candidate for Malaria Patients.
Young Yil Bahk 1,* (Professor), Sang Bong Lee2 (Graduate student), Jong Bo Kim 3 (Professor), Tong Soo Kim 4 (Dr), Sung Jong Hong 5 (Dr), Sung Kyu Ahn 6 (Dr), Dong Min Kim 7 (Professor), Sungkeun Lee 8 (Professor)
1Dept. of Biotechnology, Konkuk University Glocal Campus,
2Research Institute for Biomedical & Health Science, Konkuk University
Advancements in the field of proteomics have provided opportunities to develop diagnostic and therapeutic strategies against various diseases. About half of the world’s population remains at risk of malaria. Caused by protozoan parasites of the genus Plasmodium, malaria is one of the oldest and largest risk factors responsible for the global burden of infectious diseases with an estimated 3.2 billion persons at risk of infection. For epidemiological surveillance and appropriate treatment of individuals infected with Plasmodium spp., timely detection is critical. In this study, we used combinations of depletion of abundant plasma proteins, 2-dimensional gel electrophoresis (2-DE), image analysis, LC-MS/MS and western blot analysis on the plasma of healthy donors (100 individuals) and vivax and falciparum malaria patients (100 vivax malaria patients and 8 falciparum malaria patients). These analyses revealed that メ1-antichymotrypsin (AACT) protein levels were elevated in vivax malaria patient plasma samples (mean fold-change 【 standard error: 2.83【0.11, based on band intensities), but not in plasma from patients with other mosquito-borne infectious diseases. The results of AACT immunoblot analyses showed that AACT protein was significantly elevated in vivax and falciparum malaria patient plasma samples (∶ 2-fold) compared to healthy control donor plasma samples, which has not been previously reported.
Abstract, Accepted Manuscript(in press) [Submitted on August 26, 2022, Accepted on September 25, 2022]
  © KSBMB. All rights reserved. / Powered by INFOrang Co., Ltd